Sepsis-induced thrombocytopenia-associated multiple organ failure
张铁凝 1刘春峰 1杨妮 1林楠
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 中国医科大学附属盛京医院儿童急诊与重症医学科，沈阳 110004
折叠
摘要
脓毒症诱导的血小板减少相关多器官衰竭（TAMOF）是脓毒症相关器官功能障碍的严重亚型之一，具有较高的病死率及不良预后，临床表现特点为感染引起的新发血小板减少和多器官功能障碍。脓毒症诱导的TAMOF发病机制尚未清楚，研究显示血管性血友病因子裂解酶ADAMTS-13在TAMOF发病过程中可能发挥了重要作用。血浆置换治疗似乎有良好的前景，但需大样本随机对照试验来验证，针对血管性血友病因子和ADAMTS-13靶点研发单一治疗药物是未来治疗方向。 Sepsis-induced thrombocytopenia-associated multiple organ failure（TAMOF）is a severe subtype of sepsis-related organ dysfunctions，which has high mortality and poor prognosis.The main clinical characteristics are thrombocytopenia caused by infection and multiple organ dysfunction.However，the exact molecular mechanism of TAMOF remains unclear.The current studies have shown ADAMTS-13，which is a von Willebrand factor lyase，plays an important role during the disease.Plasma exchange could be a treatment method，but still need more large-scale randomized controlled trials to verify.In the future，von Willebrand factor and ADAMTS-13 could become the therapeutic targets for new drug development.
Abstract
Sepsis-induced thrombocytopenia-associated multiple organ failure（TAMOF）is a severe subtype of sepsis-related organ dysfunctions，which has high mortality and poor prognosis.The main clinical characteristics are thrombocytopenia caused by infection and multiple organ dysfunction.However，the exact molecular mechanism of TAMOF remains unclear.The current studies have shown ADAMTS-13，which is a von Willebrand factor lyase，plays an important role during the disease.Plasma exchange could be a treatment method，but still need more large-scale randomized controlled trials to verify.In the future，von Willebrand factor and ADAMTS-13 could become the therapeutic targets for new drug development.
关键词
脓毒症/血小板减少/脓毒症诱导的血小板减少相关多器官衰竭
Key words
Sepsis/Thrombocytopenia/Sepsis-induced thrombocytopenia-associated multiple organ failure
万方数据